QSAR model for *in vitro* gene mutation study in bacteria (Ames test) (v1.0)

GenoITS
by ProtoQSAR

GenoITS

GenoITS is a computational workflow focused on the prediction of genotoxicity using the Integrated Testing Strategy proposed by REACH. GenoITS uses 5 different QSAR models to perform the complete workflow, one per each kind of study demanded by REACH (gene mutation in bacteria; *in vitro* cytogenicity; *in vitro* gene mutation; *in vivo* cytogenicity; *in vivo* gene mutation). GenoITS also allows the users to supply their own experimental data.

GenoITS was developed as a part of the GenoQSAR research project. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101030422.

Endpoint

Human health effects: Mutagenicity. OECD 471: Bacterial reverse mutation test.
Mutagenicity refers to the induction of permanent transmissible changes in the amount or structure of the genetic material of cells or organisms. The bacterial reverse mutation test evaluates gene mutation by using amino-acid requiring strains to detect point mutationts and frameshifts.

Metrics

Training set

Experimental values	QSAR predictions	
	non-mutagenic	**mutagenic**
non-mutagenic	2048	203
mutagenic	154	2463

Validation set

Experimental values	QSAR predictions	
	non-mutagenic	**mutagenic**
non-mutagenic	553	196
mutagenic	190	685

Parameters	Training	Validation
Accuracy	0.93	0.76
Sensitivity / recall	0.94	0.78
Specificity	0.91	0.74
Precision	0.92	0.78
Negative predictive value	0.93	0.74
F-score	0.93	0.78
Matthews Correlation Coefficient	0.85	0.52
Critical Success Index	0.87	0.64
Area under the ROC	0.93	0.76

GenoITS is part of

ProtoPRED

ProtoPRED platform allows the easy, fast and user-friendly prediction of different properties of chemical compounds, using proprietary (Q)SAR models.

📞 +34 962 021 811   ✉ protopred@protoqsar.com

https://protopred.protoqsar.com/